The frequency of Treg expressing TSLPR (TSLPR+ Tregs) was increased in colon cancer and TSLPR+ Tregs exhibited stronger immunosuppressive activity compared to TSLPR- Tregs in vitro and in vivo. This evidence concerns the gene CRLF2 and colonic neoplasm.